Subscribe
fees-gavel-istock-542099686-tzahiv--1
tzahiV / iStockphoto.com
25 September 2017Americas

Gilead escapes enhanced damages in $2.5bn Idenix verdict

Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.
Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.
Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More on this story

Americas
Merck suffers blow as $2.5bn Gilead fine overturned
19 February 2018   District Judge Leonard Stark has reversed the record $2.54 billion verdict against Gilead Sciences for patent infringement, instead finding the patent in question to be invalid.
Americas
Idenix $2.5bn ruling will impede innovation, says Amgen
4 February 2020   Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York